Hua Wei

Ningbo College of Health Sciences — China

Decision Sciences · Social Sciences

7h-index459citations17works2.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Meta-analysis and systematic reviews(6), Health Systems, Economic Evaluations, Quality of Life(4), Advanced Causal Inference Techniques(4), Cancer Immunotherapy and Biomarkers(3), Economic and Financial Impacts of Cancer(3)

Publications17 total

The defatted black soldier fly meal (Hermetia illucens) improved the pathogen resistance and gut health of Nile Tilapia (Oreochromis niloticus)
Fish & Shellfish Immunology·2025· 6 cited
Acute respiratory distress syndrome caused by Chlamydia psittaci: a case report and literature review
Frontiers in Medicine·2024· 3 citedOpen Access
Study on the cost-control effect of diagnosis-related groups based on meta-analysis
Medicine·2024· 1 citedOpen Access
Quantitative bias analysis methods for summary-level epidemiologic data in the peer-reviewed literature: a systematic review
Journal of Clinical Epidemiology·2024· 3 citedOpen Access
Quantitative bias analysis methods for summary level epidemiologic data in the peer-reviewed literature: a systematic review
2024Open Access
Dexmedetomidine alleviates ferroptosis following hepatic ischemia-reperfusion injury by upregulating Nrf2/GPx4-dependent antioxidant responses
Biomedicine & Pharmacotherapy·2023· 37 citedOpen Access
Developing a Risk Assessment Tool for Cancer-related Venous Thrombosis in China: A modified Delphi-Analytic Hierarchy Process study
Research Square (Research Square)·2023· 1 citedOpen Access
Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers
Frontiers in Pharmacology·2023· 4 citedOpen Access
Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016–2020
Frontiers in Public Health·2023· 6 citedOpen Access
HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real‐world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force
Pharmacoepidemiology and Drug Safety·2022· 91 citedOpen Access
HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force
Value in Health·2022· 48 citedOpen Access
Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews
Frontiers in Immunology·2022· 22 citedOpen Access
Textual studies of nursing service policy under the perspective of policy tool
SHILAP Revista de lepidopterología·2022Open Access
Methodological quality evaluation of systematic reviews or meta-analysis of trastuzumab-based therapy for breast cancer
Medicine·2021· 2 citedOpen Access
STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies
BMJ·2021· 206 citedOpen Access
Choosing PD-1 Inhibitors in Oncology Setting, Left or Right?—Lessons From Value Assessment With ASCO-VF and ESMO-MCBS
Frontiers in Pharmacology·2020· 9 citedOpen Access
Reporting and methodological quality of systematic reviews or meta‐analyses in nursing field in <scp>C</scp>hina
International Journal of Nursing Practice·2013· 20 cited

Frequent Co-authors

Qian Jiang(6), Shunlong Ou(4), Jing Luo(4), Shirley Wang(3), Simone Pinheiro(3), Peter Arlett(3), Sebastian Schneeweiß(3), Xiaoli Qin(3), Anton Pottegård(2), William H. Crown(2), Darren M. Ashcroft(2), Eric I. Benchimol(2), Marc L. Berger(2), Gracy Crane(2), Wim Goettsch(2), Shaum Kabadi(2), David M. Kern(2), Xavier Kurz(2), Sinéad Langan(2), Takahiro Nonaka(2)